Cargando…

The Brugada syndrome: risk stratification

Thirty years after its first description, the knowledge regarding Brugada syndrome has greatly increased. Spontaneous type 1 ECG pattern (BrECG) is a well-defined prognostic marker in asymptomatic patients and is associated with a double risk of arrhythmic events during follow-up as compared to drug...

Descripción completa

Detalles Bibliográficos
Autores principales: Gaita, Fiorenzo, Cerrato, Natascia, Saglietto, Andrea, Caponi, Domenico, Calò, Leonardo, Giustetto, Carla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10132603/
https://www.ncbi.nlm.nih.gov/pubmed/37125275
http://dx.doi.org/10.1093/eurheartjsupp/suad035
_version_ 1785031418289586176
author Gaita, Fiorenzo
Cerrato, Natascia
Saglietto, Andrea
Caponi, Domenico
Calò, Leonardo
Giustetto, Carla
author_facet Gaita, Fiorenzo
Cerrato, Natascia
Saglietto, Andrea
Caponi, Domenico
Calò, Leonardo
Giustetto, Carla
author_sort Gaita, Fiorenzo
collection PubMed
description Thirty years after its first description, the knowledge regarding Brugada syndrome has greatly increased. Spontaneous type 1 ECG pattern (BrECG) is a well-defined prognostic marker in asymptomatic patients and is associated with a double risk of arrhythmic events during follow-up as compared to drug-induced ECG pattern. Due to the extreme variability of the ECG pattern over time, the spontaneous type 1 BrECG must be carefully sought, not only through periodic ECGs but especially with repeated 12-lead 24-h Holter monitoring, with V1 and V2 electrodes placed also on the second and third intercostal space, in order to explore the right ventricular outflow tract. 12-lead 24-h Holter should also be performed in all the patients with a dubious BrECG pattern even before the drug challenge with sodium channel blockers, which carries a low but definite risk of complications. In addition to spontaneous type 1, other electrocardiographic markers of increased arrhythmic risk have been described, such as first-degree AV block, QRS fragmentation, S wave in lead I and II, and increased QRS duration. The electrophysiological study in asymptomatic patients with a spontaneous ECG Brugada pattern is still under jury and further studies need to clarify its precise role.
format Online
Article
Text
id pubmed-10132603
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-101326032023-04-27 The Brugada syndrome: risk stratification Gaita, Fiorenzo Cerrato, Natascia Saglietto, Andrea Caponi, Domenico Calò, Leonardo Giustetto, Carla Eur Heart J Suppl PLACE 2022 Supplement Paper Thirty years after its first description, the knowledge regarding Brugada syndrome has greatly increased. Spontaneous type 1 ECG pattern (BrECG) is a well-defined prognostic marker in asymptomatic patients and is associated with a double risk of arrhythmic events during follow-up as compared to drug-induced ECG pattern. Due to the extreme variability of the ECG pattern over time, the spontaneous type 1 BrECG must be carefully sought, not only through periodic ECGs but especially with repeated 12-lead 24-h Holter monitoring, with V1 and V2 electrodes placed also on the second and third intercostal space, in order to explore the right ventricular outflow tract. 12-lead 24-h Holter should also be performed in all the patients with a dubious BrECG pattern even before the drug challenge with sodium channel blockers, which carries a low but definite risk of complications. In addition to spontaneous type 1, other electrocardiographic markers of increased arrhythmic risk have been described, such as first-degree AV block, QRS fragmentation, S wave in lead I and II, and increased QRS duration. The electrophysiological study in asymptomatic patients with a spontaneous ECG Brugada pattern is still under jury and further studies need to clarify its precise role. Oxford University Press 2023-04-26 /pmc/articles/PMC10132603/ /pubmed/37125275 http://dx.doi.org/10.1093/eurheartjsupp/suad035 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle PLACE 2022 Supplement Paper
Gaita, Fiorenzo
Cerrato, Natascia
Saglietto, Andrea
Caponi, Domenico
Calò, Leonardo
Giustetto, Carla
The Brugada syndrome: risk stratification
title The Brugada syndrome: risk stratification
title_full The Brugada syndrome: risk stratification
title_fullStr The Brugada syndrome: risk stratification
title_full_unstemmed The Brugada syndrome: risk stratification
title_short The Brugada syndrome: risk stratification
title_sort brugada syndrome: risk stratification
topic PLACE 2022 Supplement Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10132603/
https://www.ncbi.nlm.nih.gov/pubmed/37125275
http://dx.doi.org/10.1093/eurheartjsupp/suad035
work_keys_str_mv AT gaitafiorenzo thebrugadasyndromeriskstratification
AT cerratonatascia thebrugadasyndromeriskstratification
AT sagliettoandrea thebrugadasyndromeriskstratification
AT caponidomenico thebrugadasyndromeriskstratification
AT caloleonardo thebrugadasyndromeriskstratification
AT giustettocarla thebrugadasyndromeriskstratification
AT gaitafiorenzo brugadasyndromeriskstratification
AT cerratonatascia brugadasyndromeriskstratification
AT sagliettoandrea brugadasyndromeriskstratification
AT caponidomenico brugadasyndromeriskstratification
AT caloleonardo brugadasyndromeriskstratification
AT giustettocarla brugadasyndromeriskstratification